Summary
A limitation of clonidine therapy is the syndrome of rebound hypertension and sympathetic overactivity after withdrawal. Ten patients, four male, six female, aged 28–64 years, with essential hypertension, were treated for one year with an imidazoline derivative, tiamenidine. Blood pressure fell from an average of 178/108 mm Hg pretreatment to 152/86 mm Hg after 1 year. Tiamenidine was then withdrawn in hospital, replaced by identical placebo under single blind conditions and observations made over 96 h. The study was interrupted in five patients (4 patients within 36 h) because blood pressure rose to greater than 30 mm Hg (systolic) or greater than 20 mm Hg (diastolic) above pretreatment values. For the group, blood pressure was maximal at 194/112 mm Hg, 18 h post withdrawal, significantly higher than pretreatment (p<0.005). Headache, tremor, flushing and insomnia were noted. Saliva production rose 100% at 24 h. Plasma noradrenaline rose within 24 h with an accompanying rise in urinary metanephrine and catecholamine excretion. Tiamenidine appears to share with other imidazolines rebound cardiovascular and autonomic effects following abrupt withdrawal.
Similar content being viewed by others
References
Putzeys MR, Hoobler SW (1972) Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. Am Heart J 83: 464–468
Reid JL, Wing LMH, Dargie HJ, Hamilton CA, Davies DS, Dollery CT (1977) Clonidine withdrawal in hypertension: Changes in blood pressure and plasma and urinary noradrenaline. Lancet 1: 1171–1174
Lindner E, Kaiser J (1974) Tiamenidine (HOE 440) a new antihypertensive substance. Arch Int Pharmacodyn 211/2: 305–325
Schoelkens BA, Lindner E (1977) Central hypotensive action of tiamenidine in rats and dogs. IRCS Med Sci 5/8: 380
Findlay D, Lawrence JR (1978) An alternative method of assessing changes in salivary flow: Comparison of the effects of clonidine and tiamenidine (HOE 440). Eur J Clin Pharmacol 14: 231–235
Ellis DB, Novick WJ, Wilker JC (1979) Catecholamine excretion by spontaneous hypertensive rats on abrupt withdrawal of imidazoline antihypertensives. In: Usdin E (ed) Basic and clinical frontiers. Pergamon Press, New York, pp 1515–1517
Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S (1976) Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19: 11–17
Henry DP, Storman BJ, Johnson DG, Williams RH (1975) A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci 16: 375–384
Boyd GW, Fitz AE, Adamson AR, Peart WS (1969) Radioimmunoassay determination of plasma renin activity. Lancet 1: 213–219
Pisano JJ (1960) A simple analysis for normetanephrine and metanephrine in urine. Clin Chim Acta 5: 406–414
von Euler US, Lishajko F (1961) Improved technique for the fluorimetric estimation of catecholamines. Acta Physiol Scand 51: 348–356
Lowder SC, Hamet P, Liddel GW (1976) Contrasting effects of hypoglycaemia on plasma renin activity and cyclic adenosine 3′5′-monophosphate (cyclic AMP) in low renin and normal renin essential hypertension. Circ Res 38: 105–108
Esler MD, Nestel PJ (1973) Renin and sympathetic nervous system responsiveness in adrenergic stimuli in essential hypertension. Am J Cardiol 32: 643–649
Caldwell JR, Carretero OA (1972) Plasma renin and blood pressure after sympathetic stimulation in normotensive and hypertensive patients. Am J Cardiol 29: 466–469
Bailey RR, Neal TJ (1976) Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. Br Med J 1: 942–943
Reid JL, Dargie HJ, Davies DS, Wing LMH, Hamilton CA, Dollery CT (1977) Clonidine withdrawal in hypertension. Lancet 1: 1172–1174
Gayskes GG, Boer P, Dorhout Mees EJ (1979) Clonidine withdrawal, mechanism and frequency of rebound hypertension. Br J Clin Pharmacol 7: 55–62
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campbell, B.C., Elliott, H.L., Hamilton, C.A. et al. Changes in blood pressure, heart rate, and sympathetic activity on abrupt withdrawal of tiamenidine (HOE 440) in essential hypertension. Eur J Clin Pharmacol 18, 449–454 (1980). https://doi.org/10.1007/BF00874654
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00874654